Business Context and Reporting Period
Company: Kiora Pharmaceuticals, Inc. (KPRX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 20, 2022
Reporting Period Affected: Fiscal years ended December 31, 2021 and 2020; Quarterly periods ended March 31, 2021, June 30, 2021, and September 30, 2021.
Key Financial Metrics
This filing does not provide updated revenue, profit, cash flow, or liquidity figures. It specifically addresses a material misstatement regarding the accounting of contingent consideration liabilities.
- Holdback Shares Liability: Previously recorded as a liability of $1.353 million in connection with the Panoptes Pharma acquisition; determined to be equity.
- Contingent Consideration: Anticipated reductions in liability for earnout payments related to Jade Therapeutics, Bayon Therapeutics, and Panoptes Pharma due to extended timelines and reevaluated probabilities.
Material Changes and Restatement
The Audit Committee concluded that previously issued audited and unaudited financial statements should no longer be relied upon due to inadvertent errors in accounting for contingent consideration.
- Panoptes Pharma (Dec 2020): Holdback Shares were incorrectly classified as a liability ($1.353 million) instead of equity.
- Jade Therapeutics (Mar 2016): Contingent cash earnout liability for KIO-201 is expected to decrease due to extended development timelines (drug vs. device).
- Bayon and Panoptes (Oct 2021/Dec 2020): Contingent cash earnout liabilities are expected to decrease following a reevaluation of success probabilities and discount rates.
- Impairment Testing: The Company is evaluating the impact of these adjustments on goodwill and intangible asset impairment testing as of December 31, 2021.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to file a comprehensive amended Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which will include expanded financial information and disclosures for all affected periods, rather than filing separate amended reports for each quarter.
Risks and Contingencies:
- Reliance on previously issued earnings releases and investor communications is no longer valid.
- Forward-looking statements regarding the timing of the amended filing and the effects of the restatement are subject to risks and uncertainties.
- Potential impact on goodwill and intangible asset impairment testing remains under evaluation.
Investor Verification Checklist
- Verify the classification of the $1.353 million Holdback Shares from the Panoptes acquisition as equity rather than liability.
- Monitor the upcoming amended Form 10-K for the fiscal year ended December 31, 2021, for corrected financial statements.
- Review the impact of the restatement on goodwill and intangible asset impairment charges.
- Confirm the revised valuation of contingent consideration liabilities for Jade, Bayon, and Panoptes earnouts.